Patents by Inventor Florian WINAU

Florian WINAU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240076382
    Abstract: Antibodies, and antigen-binding fragments thereof, that specifically bind to Cluster of Differentiation 1a (CD1a) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.
    Type: Application
    Filed: July 19, 2023
    Publication date: March 7, 2024
    Applicants: Pfizer Inc., Children's Medical Center Corporation
    Inventors: Florian WINAU, Oleg V. KOVALENKO, Chew Shun CHANG, Di WU, Nicholas Andrew MARZE, Shian-Huey CHIANG
  • Patent number: 11746154
    Abstract: Antibodies, and antigen-binding fragments thereof, that specifically bind to Cluster of Differentiation 1a (CD1a) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: September 5, 2023
    Assignees: Pfizer Inc., Children's Medical Center Corporation
    Inventors: Florian Winau, Oleg V. Kovalenko, Chew Shun Chang, Di Wu, Nicholas Andrew Marze, Shian-Huey Chiang
  • Publication number: 20220112291
    Abstract: Antibodies, and antigen-binding fragments thereof, that specifically bind to Cluster of Differentiation 1a (CD1a) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.
    Type: Application
    Filed: October 7, 2021
    Publication date: April 14, 2022
    Applicants: Pfizer Inc., Children's Medical Center Corporation
    Inventors: Florian WINAU, Oleg V. KOVALENKO, Chew Shun CHANG, Di WU, Nicholas Andrew MARZE, Shian-Huey CHIANG
  • Publication number: 20190290728
    Abstract: Described herein are methods and compostions relating to breaking or inhibiting T cell exhaustion by increasing TMEM16F levels and/or activity. The methods and compositions can thereby further relate to treatment of viral infections or cancer, treatment of a chronic disease, vaccine administration, administering a CAR-T therapy, or increasing the number of T-bet+ T cells in a subject. In some embodiments, the methods relate to treatment of an autoimmune or inflammatory disease by inhibiting TMEM16F levels and/or activity.
    Type: Application
    Filed: October 20, 2017
    Publication date: September 26, 2019
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Florian WINAU, Yu HU